David Liu (Jessica Rinaldi/The Boston Globe via Getty Images)
In a pandemic boom callback, David Liu's preclinical gene editing startup debuts on Nasdaq with $175M IPO
David Liu’s CRISPR 3.0 play will officially hit Nasdaq on Thursday.
Prime Medicine priced its IPO raise with $175 million in new cash, the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
